Express Mail No.: EV475141864US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Roemer et al.

Confirmation No. 5750

Application No.: 10/018,105

Group Art Unit: 1636

Filed: November 5, 2001

Examiner: Burkhart, Michael D.

(U.S. National Stage Application of PCT/CA00/00533 filed May 5, 2000)

For:

IDENTIFICATION OF CANDIDA ALBICANS Attorney Docket No.: 10182-015-999

ESSENTIAL FUNGAL SPECIFIC GENES AND USE THEREOF IN ANTIFUNGAL

DRUG DISCOVERY

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING AND STATEMENTS UNDER 37 C.F.R. § 1.821(f) AND (g) and § 1.825

Commissioner For Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SIR:

In response to the Office Action mailed June 6, 2005 and in connection with the above-captioned application, Applicants submit herewith a Substitute Sequence Listing in written form and in computer readable form ("CRF") pursuant to 37 C.F.R. § 1.821(a), (c) and (e). Please replace the paper and CRF copies of the Substitute Sequence Listing filed November 5, 2001 with this Substitute Sequence Listing in written and CRF submitted herewith.

The undersigned hereby states that the content of the sequence listing information recorded in CRF submitted herewith is identical to the written sequence listing submitted herewith, in accordance with 37 C.F.R. § 1.821(f).

The undersigned further states that, in accordance with 37 C.F.R. § 1.821(g) and 37 C.F.R. § 1.825 (a) and (b), the written and the CRF of the Substitute Sequence Listing do not

introduce new patronic the application. Support for the amendment to the Sequence Listing is found at page 28, first 3 paragraphs, and in Figures 1 - 3 of the application as filed.

Applicants respectfully request that the Substitute Sequence Listing be entered and made of record in the above-identified application.

Respectfully submitted,

Date: December 6, 2005

By: Manual A. Coruzzi (Reg. No.)

By: Michael J. Ryan (Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures